Treatment of female infertility with recombinant human luteinising hormone: Is there a benefit over other available drugs?

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 11, 2003, Pages 1985-1994

  Shoham, Zeev ^a,b  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Assisted reproductive technology; Follicle stimulating hormone; Follicular phase; Luteal phase; Luteinising hormone; Ovarian stimulation; Recombinant FSH; Recombinant LH

Indexed keywords

BUSERELIN; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; PLACEBO; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HORMONE ACTION; HUMAN; INFERTILITY THERAPY; MENSTRUAL CYCLE; MULTIPLE PREGNANCY; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVULATION; OVULATION INDUCTION; RECOMBINANT DNA TECHNOLOGY; REVIEW;

ADULT; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OVULATION; RECOMBINANT PROTEINS;

EID: 0242574988     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.11.1985     Document Type: Review

References (87)

1. STOKMAN PG, DE LEEUW R, VAN DEN WIJNGAARD HA et al.: Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil. Steril. (1993) 60:175-178.
2. CHANNING CP, KAMMERMAN S: Binding of gonadotropins to ovarian cells. Biol. Reprod. (1974) 10:179-198.
3. MARSH JM: The role of cyclic AMP in gonadal function. Adv. Cyclic Nucleotide Res. (1975) 6:137-199.
4. RICHARDS JS, JAHNSEN T, HEDIN L et al.: Ovarian follicular development: from physiology to molecular biology. Recent Prog. Horm. Res. (1987) 43:231-276.
5. MENON KM, GUNAGA KP: Role of cyclic AMP in reproductive processes. Fertil. Steril. (1974) 25:732-750.
6. LAMPRECHT SA, ZOR U, TSAFRIRI A, LINDNER HR. Action of prostaglandin E2 and of luteinising hormone on ovarian adenylate cyclase, protein kinase and ornithine decarboxylase activity during postnatal development and maturity in the rat. J. Endocrinol. (1973) 57:217-233.
7. MARSH JM: The role of cyclic AMP in gonadal steroidogenesis. Biol. Reprod. (1976) 14:30-53.
8. CHANNING CP, VILLEE CA: Stimulation of cholesterol metabolism in the luteinized rat ovary by luteinising hormone. Biochim. Biophys. Acta (1966) 127:1-17.
9. ARMSTRONG DT, LEE TP, MILLER LS: Stimulation of progesterone biosynthesis in bovine corpora lutea by luteinising hormone in the presence of an inhibitor of cholesterol synthesis. Biol. Reprod. (1970) 2:29-36.
10. SHERIZLY I, GALIANI D, DEKEL N: Regulation of oocyte maturation: communication in the rat cumulus-oocyte complex. Hum. Reprod. (1988) 3:761-766.
11. BEHRMAN HR, AMSTRONG DT: Cholesterol esterase stimulation by luteinising hormone in luteinized rat ovaries. Endocrinology (1969) 85:474-480.
12. ROBINSON J, STEVENSON PM, BOYD GS, ARMSTRONG DT. Acute in vivo effects on HCG and LH on ovarian mitochondrial cholesterol utilization. Mol. Cell. Endocrinol. (1975) 2:149-155.
13. CARON MG, GOLDSTEIN S, SAVARD K, MARSH JM: Protein kinase stimulation of a reconstituted cholesterol side chain cleavage enzyme system in the bovine corpus luteum. J. Biol. Chem. (1975) 250:5137-5143.
14. FEVOLD HL: Synergism of follicle stimulating and luteinising hormones in producing estrogen secretion. Endocrinology (1941) 28:33-36.
15. SHORT RV: Steroids in the follicular fluid and the corpus luteum of the mare. A 'two-cell type' theory of ovarian steroid synthesis. J. Endocrinol. (1962) 24:59-63.
16. RYAN KJ, PETRO Z, KAISER J: Steroid formation by isolated and recombined ovarian granulosa and tehcal cells. J. Clin. Endocrinol. Metab. (1968) 28:355-358.
17. COUZINET B, LESTRAT N, BRAILLY S, FOREST M, SCHAISON G: Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. J. Clin. Endocrinol Metab. (1988) 66:552-556.
18. SHOHAM Z, BALEN A, PATEL A, JACOBS HS: Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil. Steril. (1991) 56:1048-1053.
19. THE EUROPEAN RECOMBINANT HU6MAN LH STUDY GROUP: Recombinant human luteinising hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J. Clin. Endocrinol. Metab. (1998) 83:1507-1514.
20. CHABBERT-BUFFET N, BOUCHARD P: The normal human menstrual cycle. Rev. Endocrinol. Metab. Disord. (2002) 3:173-183.
21. SEIBEL MM, SMITH DM, LEVESQUE L, BORTEN M, TAYMOR ML: The temporal relationship between the luteinising hormone surge and human oocyte maturation. Am. J. Obstet. Gynecol. (1982) 142:568-572.
22. ITSKOVITZ-ELDOR J, LEVRON J, KOL S: Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimulation syndrome. Clin. Obstet. Gynecol. (1993) 36:701-710.
23. PELUSO JJ: Role of the amplitude of the gonadotropin surge in the rat. Fertil. Steril. (1990) 53:150-154.
24. HOFF JD, QUIGLEY ME, YEN SS: Hormonal dynamics at midcycle: a reevaluation. J. Clin. Endocrinol. Metab. (1983) 57:792-796.
25. FRITZ MA, MCLACHLAN RI, COHEN NL et al.: Onset and characteristics of the midcycle surge in bioactive and immunoactive luteinising hormone secretion in normal women: influence of physiological variations in periovulatory ovarian steroid hormone secretion. J. Clin. Endocrinol. Metab. (1992) 75:489-493.
26. CARGILLE CM, ROSS GT, YOSHIMI T: Daily variations in plasma follicle stimulating hormone, luteinising hormone and progesterone in the normal menstrual cycle. J. Clin. Endocrinol. Metab. (1969) 29:12-19.
27. SHOHAM Z, SCHACTER M, LOUMAYE E et al.: The luteinising hormone surge-the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil. Steril. (1995) 64:237-251.
28. TRINCHARD-LUGAN I, KHAN A, PORCHET HC, MUNAFO A: Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. Reprod. Biamed. Online (2002) 4:106-115.
29. LE COTONNEC JY, LOUMAYE E, PORCHET HC, BELTRAMI V, MUNAFO A: Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinising hormone and recombinant human follicle-stimulating hormone. Fertil. Steril. (1998) 69:201-209.
30. LE COTONNEC JY, PORCHET HC, BELTRAMI V, MUNAFO A: Clinical pharmacology of recombinant human luteinising hormone: Part II. Bioavailability of recombinant human luteinising hormone assessed with an Immunoassay and an in vitro bioassay. Fertil. Steril. (1998) 69:195-200.
31. LE COTONNEC JY, PORCHET HC, BELTRAMI V, MUNAFO A: Clinical pharmacology of recombinant human luteinising hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinising hormone. Fertil. Steril. (1998) 69:189-194.
32. DAMEWOOD MD, SHEN W, ZACUR HA et al.: Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril. (1989) 52:398-400.
33. BRAUNSTEIN GD, BLOCH SK, RASOR JL, WINIKOFF J: Characterization of antihuman chorionic gonadotropin serum antibody appearing after ovulation induction. J. Clin. Endocrinol. Metab. (1983) 57:1164-1172.
34. KYLE CV, GRIFFIN J, JARRETT A, ODELL WD: Inability to demonstrate an ultrashort loop feedback mechanism for luteinising hormone in humans. J. Clin. Endocrinol. Metab. (1989) 69:170-176.
35. NADERS, BERKOWITZ AS: Endogenous luteinising hormone surges following administration of human chorionic gonadotropin: further evidence for lack of loop feedback in humans. J. Assist. Reprod. Genet. (1992) 9:124-127.
36. DEMOULIN A, DUBOIS M, GERDAY C et al.: Variations of luteinising hormone serum concentrations after exogenous human chorionic gonadotropin administration during ovarian hyperstimulation. Fertil. Steril. (1991) 55:797-804.
37. GOLAN A, RON-EL R, HERMAN A et al.: Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. (1989) 44:430-440.
38. GIDLEY-BAIRD AA, O'NEILL C, SINOSICH MJ et al.: Failure of implantation in human in vitro fertilisation and embryo transfer patients: the effects of altered progesterone/estrogen ratios in humans and mice. Fertil. Steril. (1986) 45:69-74.
39. FORMAN R, FRIES N, TESTART J et al.: Evidence for an adverse effect of elevated serum oestradiol concentrations on embryo implantation. Fertil. Steril. (1988) 49:118-122.
40. ABBASI R, KENIGSBERG D, DANFORTH D, FALK RJ, HODGEN GD: Cumulative ovulation rate in human menopausal/human chorionic gonadotropin-treated monkeys: 'step-up' versus 'step-down' dose regimens. Fertil. Steril. (1987) 47:1019-1024.
41. RANASINGHE L: Recombinant technology in medical research and therapeutics. Ceylon Med. J. (1983) 28:57-61.
42. ARUFFO A, SEED B: Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl. Acad. Sci. USA (1987) 84:8573-8577.
43. JULIUS D, MACDERMOTT AB, AXEL R, JESSELL TM: Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science (1988) 241:558-564.
44. SIMPSON AJ, WALKER T, TERRY R: An introduction to recombinant DNA technology. Parasitology (1986) 92(Suppl.):S7-S14.
45. FONG Y, MOLDAWER LL, LOWRY SF: Experimental and clinical applications of molecular cell biology in nutrition and metabolism. J. Parenter. Enteral Nutr. (1992) 16:477-486.
46. PORCHET HC, LE COTONNEC JY, NEUTEBOOM B, CANALI S, ZANOLO G: Pharmacokinetics of recombinant human luteinising hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinising hormone. J. Clin. Endocrinol. Metab. (1995) 80:667-673.
47. SHOHAM Z, INSLER V: Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil. Steril. (1996) 66:187-201.
48. HOWLES CM: Genetic engineering of human FSH (Gonal-F). Hum. Reprod. Update (1996) 2:172-191.
49. PIERCE JG, PARSONS TF: Glycoprotein hormones: structure and function. Ann. Rev. Biochem. (1981) 50:465-495.
50. KEUTMANN HT, DAWSON B, BISHOP WH, RYAN RJ: Structure of human luteinising hormone alpha subunit. Endocr. Res. Commun. (1978) 5:57-70.
51. PAREKH RB, PATEL TP: Comparing the glycosylation patterns of recombinant glycoproteins. Trends Biotech. (1992) 10:276-280.
52. ULLOA-AGUIRRE A, ESPINOZA R, DAMIAN-MATSUMURA P, CHAPPEL SC: Immunological and biological potencies of the different molecular species of gonadotrophins. Hum. Reprod. (1988) 3:491-501.
53. GREEN ED, BAENZIGER JU: Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. I. Structural elucidation of the sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones. J. Biol. Chem. (1988) 263:25-35.
54. NAYLOR SL, CHIN WW, GOODMAN HM et al.: Chromosome assignment of genes encoding the alpha and beta subunits of glycoprotein hormones in man and mouse. Somatic Cell Genet. (1983) 9:757-770.
55. VANDE WIELE RL, BOGUMIL J, DYRENFURTH I et al.: Mechanisms regulating the menstrual cycle in women. Recent Prog. Horm. Res. (1970) 26:63-103.
56. RABAU E, DAVID A. SERR DM, MASHIACH S, LUNENFELD B: Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am. J. Obstet. Gynecol. (1967) 98:92-98.
57. BAER G, LOUMAYE E: Comparison of recombinant human luteinising hormone (rhLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology. Curr. Med. Res. Opin. (2003) 19:83-88.
58. BROWN JB: Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust. NZ. J. Obstet. Gynaecol. (1978) 18:46-54.
59. SHOHAM Z, MANNAERTS B, INSLER V, COELINGH-BENNINK H: Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil. Steril. (1993) 59:738-742.
60. SCHOOT DC, HARLIN J, SHOHAM Z et al.: Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women. Hum. Reprod (1994) 9:1237-1242.
61. SCHOOT DC, COELINGH BENNINK HJ, MANNAERTS BM et al.: Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. J. Clin. Endocrinol. Metab. (1992) 74:1471-1473.
62. BALASCH J, FABREGUES F: Pregnancy after administration of high dose recombinant human LH alone to support final stage of follicular maturation in a women with a long-standing hypogonadotropic hypogonadism. Reprod. Biomed. Online (2003) 6:427-431.
63. BALASCH J, FABREGUES F, CASAMITJANA R, PENARRUBIA J, VANRELL JA: A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome. Reprod. Biomed. Online (2003) 6:296-301.
64. PORTER RN, SMITH W, CRAFT IL, ABDULWAHID NA, JACOBS HS: Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet (1984) 2:1284-1285.
65. LOUMAYE E, ENGRAND P, HOWLES CM, O'DEA L: Assessment of the role of serum luteinising hormone and oestradiol response to follicle-stimulating hormone on in vitro fertilisation treatment outcome. Fertil. Steril. (1997) 67:889-899.
66. SILLS ES, LEVY DP, MOOMJY M, MCGEE M, ROSENWAKS Z: A prospective, randomised comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinising hormone in in-vitro fertilisation. Hum. Reprod. (1999) 14:2230-2235.
67. BEN-AMOR A-F ON BEHALF OF THE STUDY GROUP: The effect of luteinising hormone administered during late follicular phase in normo-ovulatory women undergoing in vitro fertilisation. Hum. Reprod. (2000) 15:46 (Abstract).
68. MARRS R, MELDRUM D, MUASHER S, SCHOOLCRAFT W, WERLIN L, KELLY E: Does the addition of LH have a benefit for patients of advanced reproductive age undergoing ART? A randomised comparative trial of recombinant human FSH (Gonal-F) alone or in combination with recombinant human LH from day 6 of treatment. Reprod. Biomed. Online (2003) (In Press).
69. IMTHURN B, PIAZZI A, LOUMAYE E: Recombinant human luteinising hormone to mimic mid-cycle LH surge. Lancet (1996) 348:332-333.
70. Human recombinant luteinising hormone is as effective as, but safer than, urinary human chorionic gonadottopin in inducing final follicular maturation and ovulation in in vitro fertilisation procedures: results of a multi-centre double-blind study. J. Clin. Endocrinol. Metab. (2001) 86:2607-2618.
71. BALASCH J, HOWLES CM: GnRH agonist protocols: which one to use? In: Female Infertility Therapy; Current Practice. Shoham Z, Howles CM, Jacobs HS (Eds), Martin Dunitz, London, UK (1999):189-201.
72. CHRISP P, GOA KL: Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs (1990) 39:523-551.
73. LISI F, RINALDI L, FISHEL S et al.: Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online (2002) 5:104-108.
74. LISI F, RINALDI L, FISHEL S et al: Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod. Biomed. Online (2001) 3:190-194.
75. ESPOSITO MA, BARNHART KT, COUTIFARIS C, PATRIZIO P: Role of periovulatory luteinising hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil. Steril. (2001) 75:519-524.
76. LOUMAYE E: Do all women need LH for ovarian stimulation? Ben-Rafael Z, Frydman R, Shoham Z (Eds), Monduzzi Publisher, Bologna, Italy (2001):9-15.
77. WESTERGAARD LG, LAURSEN SB, ANDERSEN CY: Increased risk of early pregnancy loss by profound suppression of luteinising hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum. Reprod. (2000) 15:1003-1008.
78. FLEMING R, REHKA P, DESHPANDE N et al.: Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum. Reprod (2000) 15:1440-1445.
79. MERVIEL PH, ANTOINE JM, BOUTLANE-IRAKI B et al.: LH concentrations after GnRH antagonist administration do not have any influence on pregnancy rates in IVF-embryo transfer. Hum. Reprod. Abstracts (2002) Num 0-007.
80. NOYES N, CHUNG K, KATZ J, KREY L: Is exogenous LH necessary when using GnRH antagonists in IVF ovarian hyperstimulation? Fertil. Steril. (2002) 76:S22.
81. LOUMAYE E, ENGRAND P, SHOHAM Z, HILLIER SG, BAIRD DT. Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization Type I and Type II anovulation. Hum. Reprod (2003) 18:314-322.
82. SHOHAM Z: The clinical therapeutic window for luteinising hormone in controlled ovarian stimulation. Fertil. Steril. (2002) 77:1170-1177.
83. HILLIER SG: Current concepts of the roles of follicle stimulating hormone and luteinising hormone in folliculogenesis. Hum. Reprod. (1994) 9:188-191.
84. FILICORI M, COGNIGNI GE, TARABORRELLI S et al.: Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J. Clin. Endocrinol. Metab. (2001) 86:337-343.
85. FILICORI M, COGNIGNI GE, TARABORRELLI S et al.: Luteinising hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J. Clin. Endocrinol. Metab. (1999) 84:2659-2663.
86. FILICORI M, COGNIGNI GE, POCOGNOLI P et al.: Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum. Reprod. (2002) 17:2009-2015.
87. FILICORI M, COGNIGNI GE, TABARELLI C et al.: Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J. Clin. Endocrinol. Metab. (2002) 87:1156-1161.